SkinTE is a personalized therapy created from a patient's own skin sample. Despite the complexity of harvesting cells, processing them, and activating them into a healing state, Polarity Bio has streamlined logistics to deliver the final product back to the clinic for application in just four to ten days, which is critical for treating active wounds.

The company's therapy uses transient engineering with a single mRNA strand to deliver both anti-inflammatory and anti-fibrotic payloads into a patient's own macrophages. This enhances the cells' natural healing abilities, aiming to reduce inflammation and resolve fibrotic scars to allow organs like the liver to regenerate.

Eupraxia's technology is defined by its precision: delivering a stable, flat dose directly into target tissue for up to a year. This hyper-local approach mimics the stability of a continuous IV infusion, aiming to maximize efficacy while minimizing systemic side effects caused by the 'peaks and troughs' of conventional pills or injections.

Moving from Phase 2 to Phase 3 trials, Polarity Bio didn't just increase patient numbers; it doubled the follow-up period from three to six months. This shift highlights a critical goal of late-stage trials: assessing the long-term durability of a treatment's effect—in this case, ensuring the healed wounds remain closed.

Medicine is shifting from a 200-year-old paradigm of using chemical drugs to block symptoms toward a new era of cell and gene therapies. This new approach fundamentally changes treatment by directly addressing the root cause of disease: repairing or replacing the faulty cells and genes themselves.

Many current gene therapies require a complex "ex vivo" process: removing cells, reprogramming them in a lab, and reinfusing them. The true breakthrough is developing "in vivo" treatments administered via a simple infusion that autonomously target the correct cells within the body.

Unlike treatments like microneedling that wound skin to trigger a healing and collagen-building response, red light therapy operates differently. It stimulates mitochondria to increase cellular energy (ATP). This energizes cells responsible for building collagen without causing any initial damage, offering a less invasive anti-aging pathway.

The company's stromal cells don't function like typical "stem cells" that replace tissue. Instead, they act as immunomodulatory factories. Cytokines from an immune response activate receptors on the cells, which then release anti-inflammatory factors to turn off that specific inflammation, acting as a targeted signaling response.

The body's innate ability to regenerate skin relies on cells located around hair follicles. When a wound is superficial, these cells can repair the damage. However, for deep wounds that go beneath the follicle level, this natural healing mechanism is lost, necessitating advanced treatments like Polarity Bio's SkinTE.